Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | RXRA | P19793 | 5/20 | 0.67 |
| ▸ | RARA | P10276 | 4/20 | 0.67 |
| ▸ | RARB | P10826 | 4/20 | 0.67 |
| ▸ | RARG | P13631 | 4/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.67 |
| ▸ | APP | P05067 | 4/20 | 0.67 |
| ▸ | SNCA | P37840 | 4/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.67 |
| ▸ | BLM | P54132 | 3/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | RXRB | P28702 | 2/20 | 0.67 |
| ▸ | RXRG | P48443 | 2/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL5182511 | 1.00 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL3643432 | 0.90 | ALDH1A1 (0.72) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL6424110 | 0.89 | ALDH1A1 (0.71) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL3643434 | 0.89 | ALDH1A1 (0.74) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL14164136 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL21427636 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL13124361 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL14161069 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA | |
| SCHEMBL14300778 | 0.88 | ALDH1A1 (0.67) | ALDH1A1MAPTCYP3A4RXRARARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016130816-A1 | INHIBITORS OF MYELOID LEUKEMIA CELL GROWTH AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-08-18 | — | — | WO | claimed |
| US-20130237505-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | CONCERT, LLC (US) | 2013-09-12 | — | — | US | claimed |
| US-20080139518-A1 | Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide | CONCERT, LLC | 2008-06-12 | — | — | US | claimed |
| US-5837728-A | ACNE AND OTHER SKIN DISORDERS; ANTIAGING, ANTIWRINKLING AND WOUND HEALING AGENTS; SIDE EFFECT REDUCTION | MOLECULAR DESIGN INTERNATIONAL (US) | 1998-11-17 | — | — | US | claimed |
| WO-1997032839-A9 | 9-CIS-RETINOIC ACID ESTERS AND AMIDES AND USES THEREOF | — | 1998-07-16 | — | — | WO | claimed |
| WO-2016130816-A1 | INHIBITORS OF MYELOID LEUKEMIA CELL GROWTH AND RELATED METHODS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-08-18 | — | — | WO | disclosed |
| US-20150005266-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | MOLECULAR DESIGN INTERNATIONAL, INC. | 2015-01-01 | — | — | US | disclosed |
| US-8912175-B1 | Topical compositions for treatment of skin conditions | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8865694-B2 | Topical compositions for treatment of skin conditions | MOLECULAR DESIGN INTERNATIONAL, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20140066414-A2 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | MOLECULAR DESIGN INTERNATIONAL, INC. | 2014-03-06 | — | — | US | disclosed |
| US-20130237505-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | CONCERT, LLC (US) | 2013-09-12 | — | — | US | disclosed |
| US-20080139518-A1 | Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide | CONCERT, LLC | 2008-06-12 | — | — | US | disclosed |
| US-5837728-A | ACNE AND OTHER SKIN DISORDERS; ANTIAGING, ANTIWRINKLING AND WOUND HEALING AGENTS; SIDE EFFECT REDUCTION | MOLECULAR DESIGN INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005266-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | RARA, RARB, CUTA | ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885 |
| US-20130237505-A1 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | RARA, RARB, CUTA | ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885 |
| US-20140066414-A2 | TOPICAL COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS | RARA, RARB, CUTA | ALDH1A1 281/4885MAPT 3408/4885CYP3A4 4320/4885 |
| US-20080139518-A1 | Synergistic effect attributable to combination of a retinoid component and a salicylic acid component; combination of the two active ingredients provided a greater overall anti-acne effect than a treatment comprising benzoyl peroxide | RARA, RARB, CHUK | ALDH1A1 165/4885MAPT 4791/4885CYP3A4 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.